Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research
Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research
Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research
Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research
Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research
Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research
Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research
Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research
Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research
Rosai-Dorfman Disease of Nasal Soft Tissue: A Case Report
This report aims to present a case of RDD involving the nasal soft tissues, presenting with nasal congestion and rhinorrhea as the primary complaints. The patient underwent surgery navigated by nasal endoscope did not report recurrence after operation.PMID:37740427 | DOI:10.1177/01455613231195160 (Source: Ear, Nose and Throat Journal)
Source: Ear, Nose and Throat Journal - September 23, 2023 Category: ENT & OMF Authors: Liwen Wang Huicheng Gong Linlan Jiang Shuyi Gao Yuenong Jiao Source Type: research
Rosai-Dorfman Disease of Nasal Soft Tissue: A Case Report
This report aims to present a case of RDD involving the nasal soft tissues, presenting with nasal congestion and rhinorrhea as the primary complaints. The patient underwent surgery navigated by nasal endoscope did not report recurrence after operation.PMID:37740427 | DOI:10.1177/01455613231195160 (Source: Ear, Nose and Throat Journal)
Source: Ear, Nose and Throat Journal - September 23, 2023 Category: ENT & OMF Authors: Liwen Wang Huicheng Gong Linlan Jiang Shuyi Gao Yuenong Jiao Source Type: research
Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283295. Online ahead of print.ABSTRACTStandard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dab...
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Eily Cournoyer Justin Ferrell Susan Sharp Anish Ray Michael Jordan Christopher Dandoy Michael Grimley Somak Roy Robert Lorsbach Arnold C Merrow Adam Nelson Allison Bartlett Jennifer Picarsic Ashish Kumar Source Type: research
Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283295. Online ahead of print.ABSTRACTStandard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dab...
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Eily Cournoyer Justin Ferrell Susan Sharp Anish Ray Michael Jordan Christopher Dandoy Michael Grimley Somak Roy Robert Lorsbach Arnold C Merrow Adam Nelson Allison Bartlett Jennifer Picarsic Ashish Kumar Source Type: research
Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283295. Online ahead of print.ABSTRACTStandard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dab...
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Eily Cournoyer Justin Ferrell Susan Sharp Anish Ray Michael Jordan Christopher Dandoy Michael Grimley Somak Roy Robert Lorsbach Arnold C Merrow Adam Nelson Allison Bartlett Jennifer Picarsic Ashish Kumar Source Type: research
Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283295. Online ahead of print.ABSTRACTStandard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dab...
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Eily Cournoyer Justin Ferrell Susan Sharp Anish Ray Michael Jordan Christopher Dandoy Michael Grimley Somak Roy Robert Lorsbach Arnold C Merrow Adam Nelson Allison Bartlett Jennifer Picarsic Ashish Kumar Source Type: research
